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Introduction {#s1}
============

The main strategy for the prevention of childhood lead poisoning in the United States has been targeted early detection, followed by interventions to reduce exposure ([@c2]; [@c26]). Beginning in 1989, as a key element of this strategy, the Centers for Medicare and Medicaid Services (CMS) required that all Medicaid-enrolled children be screened for blood lead levels (BLLs) at 12 and 24 months of age ([@c19]). This requirement was based on an important determinant of high BLL: living in older, poorly maintained housing with surfaces coated with lead paint and other sources of lead such as lead piping and solder ([@c21]). Economically disadvantaged families eligible for public assistance, such as Medicaid, are likely to live in such housing ([@c26]).

There has been a gradual expansion in screening beyond the earlier strategy of universal blood lead screening of Medicaid-enrolled children ([@c26]). CDC blood lead screening recommendations, updated in 1997, 2009, and 2012 encouraged state and local agencies to explore different ways to target subgroups of children with greater likelihood of having high BLLs ([@c2], [@c3]; [@c26]). Following the CDC recommendations issued in 2012 ([@c3]), the CMS began to allow states to switch from universal screening of Medicaid-enrolled children to using a customized approach based on the local distribution pattern of high BLLs across various subgroups of young children ([@c7]). Children participating in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) have been identified as an additional target in the CDC recommendations ([@c2]; [@c26]). WIC, a federal program, provides supplemental foods, nutrition education, and health care referrals (including a referral for a blood lead test required in the absence of an existing test result) to low-income pregnant and postpartum women and infants and children up to 5 y of age through state-level grants (M. Kealey, written communication, January 2015) and ([@c23]). There has been a scarcity of reports regarding BLLs on WIC participants ([@c8]; [@c28]). This study aimed to investigate whether children participating in WIC and not enrolled in Medicaid have higher BLLs than children in neither of these programs.

Methods {#s2}
=======

Design and Population {#s2.1}
---------------------

This is a cross-sectional analysis of U.S. children, 1--5 y of age, using data from the National Health and Nutrition Examination Survey (NHANES), conducted by the National Center for Health Statistics (NCHS) ([@c6]). NHANES is based on a representative sample of the U.S. noninstitutionalized civilian population selected through a multistage probability design. Since 1999, NHANES has been conducted annually and released in 2-y cycles. The survey includes household interviews and examinations, with whole blood collection through venipuncture, at mobile examination centers. Participants $\geq 1\; y$ of age were eligible for venipuncture. A family member answered a questionnaire for children $< 5\; y$ of age. For the four 2-y NHANES data releases from 2007 to 2014, examination response rates for children 1--5 y of age ranged from 74.6% to 86.8% ([@c5]). The surveys were approved by the NCHS Ethics Review Board, and written parental consent was obtained for children $< 5\; y$ of age.

Blood Lead {#s2.2}
----------

Whole blood samples were collected by venipuncture and stored frozen at $- 20{^\circ}C$ or lower until analyzed for whole blood lead at the National Center for Environmental Health, CDC, Atlanta, Georgia, using inductively coupled plasma mass spectrometry with a lower limit of detection of $0.07\;\mu g/\text{dL}$ ([@c12]). BLLs were dichotomized, $\geq$ versus $< 5\;\mu g/\text{dL}$, based on the reference value defined by CDC in 2012 ([@c3]). For this study, a BLL $\geq 5\;\mu g/\text{dL}$ was defined as a high BLL. The reference value of $5\;\mu g/\text{dL}$ was the 97.5th percentile for children 1--5 y of age observed in NHANES 2009--2012 ([@c4]). Increment in BLLs below $5\;\mu g/\text{dL}$ has been associated with lower intellectual function ([@c15]; [@c17]).

WIC Participation and Medicaid Enrollment {#s2.3}
-----------------------------------------

WIC participation was determined by a home interview question: "Did the survey participant receive benefits from WIC, that is, the Women, Infants, and Children program, in the past 12 months?" Medicaid enrollment status was determined based on a positive response to either of the two home interview questions: "Is the survey participant covered by Medicaid?" and "Is the survey participant covered by SCHIP (State Children's Health Insurance Program)?" Based on self-reported WIC and Medicaid statuses, a combined WIC/Medicaid status variable with four categories ("WIC and Medicaid," "WIC only," "Medicaid only," and "neither") was derived. We also examined high BLL among low-income children whose parents or guardians did not report participation in WIC or enrollment in Medicaid, using the WIC eligibility criteria of a family income-to-poverty ratio (FIPR) of $\leq 1.85$. The FIPR was calculated using the family income reported in the NHANES interview and the Department of Health and Human Services' poverty guidelines. The analysis of children who were not in either WIC or Medicaid compared those children with an FIPR $\leq 1.85$ (income eligible for WIC) to those with an FIPR $> 1.85$ (income ineligible for WIC) or missing family income data.

Other Variables {#s2.4}
---------------

Age, race/Hispanic origin, and urbanization have been associated with BLLs in previous studies ([@c1]; [@c27]). Age in years was recorded at the time of the NHANES household interview and was used as a discrete variable and dichotomized as 1--2 versus 3--5 y of age because CMS has required universal screening by Medicaid of children at 1 and 2 y of age. Race/Hispanic origin groups were non-Hispanic white, non-Hispanic black, Mexican American, and other (other Hispanic and all other combined including multiracial). Urbanization, based on the county of residence and the 2006 NCHS Urban--Rural Classification Scheme for Counties ([@c9]), was defined as large metro (large central metropolitan and large fringe metropolitan), medium metro (medium metropolitan and small metropolitan), and rural (micropolitan and noncore). Urbanization was not included in the public use NHANES data files due to disclosure reasons but is accessible through the NCHS Research Data Center (<https://www.cdc.gov/rdc>/).

Analytic Sample {#s2.5}
---------------

A total of 4,685 children 1--5 y of age were examined in NHANES 2007--2014. Of those, 1,501 had missing blood lead data (largely due to parental refusal for phlebotomy), 9 had missing reported WIC status, and 1 had missing county of residence (some were missing $> 1$ of these variables). The remaining 3,180 children 1--5 y of age with complete data made up the analytic sample for this study. The age range of 1--5 y has been typically used in previous studies of blood lead in young children ([@c13]; [@c26]; [@c27]) and coincides with WIC eligibility age criterion (i.e., up to the fifth birthday) ([@c23]), given the time window for which WIC participation was determined in this study (i.e., the past 12 months prior to the home interview).

Statistical Analysis {#s2.6}
--------------------

All results, excepted for the reweighted results, were weighted using publicly available examination weights to account for different probabilities of selection, nonresponse, and noncoverage ([@c11]). The reweighted analyses were weighted using the publicly available examination weights modified to reflect the population composition by domains defined by survey cycle, age in years, race/Hispanic origin, and sex, which was intended by the design of NHANES. Variances of estimates were calculated using Taylor series linearization per NHANES analysis guidelines, incorporating the complex sample design. We used prevalence ratios primarily as measures of association. Wald tests for testing group differences were performed on log(prevalence ratio), as was construction of confidence intervals (CIs) with back-transformation. Stata (version 13.0; College Station, TX) was used for all analyses.

Log-binomial regression ([@c18]), unlike logistic regression, allows direct estimation of prevalence ratios and was used to model associations between WIC/Medicaid status and high BLL prevalence, with or without adjustment for age (1--2 vs. 3--5 y). We were primarily interested in the association among children 1--2 y of age, that is, the age range historically targeted in childhood blood lead screening ([@c19]; [@c2]; [@c26]). This historical target age range was based on the fact that the mouthing behavior leading to ingestion of lead dust and chips is most frequent for these ages with the highest BLLs observed at approximately 2 y of age ([@c20]), providing opportunities to prevent mouthing-related exposure through measures such as lead abatement/removal and residential relocation. Beyond 2 y of age, BLLs tend to decline with diminishing options for specific exposure-reducing intervention ([@c4]). A simple and obvious approach for obtaining results directly relevant to 1--2 y of age (i.e., to limit the age of the analytic sample to 1--2 y) was considered but eventually not chosen as the main approach because it would have resulted in a substantial reduction in sample size. Instead, we performed age-adjusted analyses using the wider age range (1--5 y), but examined: *a*) potential effect modification by age by fitting an expanded model with age (1--2 vs. 3--5 y) and WIC/Medicaid status interaction terms and comparing a model with and without the interaction terms, and *b*) differences between unadjusted and adjusted prevalence ratios. In the absence of effect modification by age, age-adjusted prevalence ratios would represent the association between WIC/Medicaid status and high BLL for all children in the study, including children in the 1- to 2-y age range. Race/Hispanic origin and urbanization of residence have also been associated with BLLs ([@c1]; [@c27]). Therefore, we repeated models after adjusting for these factors in addition to age and compared the resulting estimates to those from the primary model. These models with adjustment for race/Hispanic origin and/or urbanization were considered secondary to the primary model without such adjustment because our primary aim was to compare actual population prevalence rather than to estimate the association between WIC/Medicaid status and high BLL while holding other population characteristics constant. We also examined the effect modification of WIC/Medicaid status--high BLL association by race/Hispanic origin and/or urbanization by fitting an expanded model with product terms representing the interaction between WIC/Medicaid status and candidate effect modifiers and testing all coefficients for the product terms being zero.

Sensitivity Analysis {#s2.7}
--------------------

To assess possible nonresponse bias due to missing blood lead measurements indirectly, we compared results based on two weighting schemes: (*a*) using publicly available examination weights, and (*b*) "reweighting" (also known as "poststratification adjustment") ([@c14]) using examination weights modified to restore the national-level population composition intended in NHANES' design.

Results {#s3}
=======

The sensitivity analysis revealed that reweighting resulted in relatively small changes ([Tables 1](#t1){ref-type="table"}--[3](#t2){ref-type="table"}; see also Tables S1--S3), specifically, within $\pm 15\%$ for the estimated prevalence ratios ([Tables 2](#t2){ref-type="table"}--[3](#t3){ref-type="table"}; see also Tables S2--S3). Therefore, we report results based on the unmodified publicly available examination weights.

###### 

Sample size, weighted percentage distribution, and prevalence of high BLLs by selected characteristics for U.S. children 1--5 y of age, NHANES 2007--2014.

Table 1 lists characteristics in the first column; the corresponding sample size and percentage distribution and prevalence of blood lead levels greater than or equal to 5 micrograms per deciliter are listed in the other columns.

  Characteristics                                                                    Sample size and percentage distribution   Prevalence of BLLs $\geq 5\;\mu g/\text{dL}$                                                                                             
  ---------------------------------------------------------------------------------- ----------------------------------------- ---------------------------------------------- ----------------------------------------------------------------------------------------- -------------
  Total                                                                              3,180                                     100.0                                          1.9 (1.3, 2.9)                                                                                   
  Age at screening (y)                                                                                                                                                                                                                                                         
   1--2                                                                              1,453                                     37.5                                           2.5 (1.7, 4.6)                                                                             (Reference)
   3--5                                                                              1,727                                     62.5                                           1.6 (1.4, 3.8)[^*b*^](#t1n2){ref-type="table-fn"}                                             0.16
  Sex                                                                                                                                                                                                                                                                          
   Male                                                                              1,669                                     51.0                                           2.1 (1.3, 3.4)                                                                             (Reference)
   Female                                                                            1,511                                     49.0                                           1.7 (1.1, 2.6)                                                                                0.35
  Race/Hispanic origin[^*c*^](#t1n3){ref-type="table-fn"}                                                                                                                                                                                                                      
   Non-Hispanic white                                                                871                                       48.8                                           1.9 (0.9, 4.0)[^*b*^](#t1n2){ref-type="table-fn"}                                          (Reference)
   Non-Hispanic black                                                                756                                       14.9                                           4.0 (2.8, 5.9)                                                                                0.07
   Mexican American                                                                  841                                       19.0                                           1.1 (0.5, 2.3)[^*b*^](#t1n2){ref-type="table-fn"}^,^[^*d*^](#t1n4){ref-type="table-fn"}       0.36
  WIC status                                                                                                                                                                                                                                                                   
   Not participated                                                                  1,381                                     55.7                                           1.4 (0.7, 2.9)[^*b*^](#t1n2){ref-type="table-fn"}                                          (Reference)
   Participated                                                                      1,799                                     44.3                                           2.6 (1.7, 3.8)                                                                                0.11
  Medicaid status                                                                                                                                                                                                                                                              
   Not enrolled                                                                      1,716                                     63.8                                           1.5 (0.9, 2.5)                                                                             (Reference)
   Enrolled                                                                          1,464                                     36.2                                           2.7 (1.9, 4.0)                                                                                0.007
  WIC/Medicaid status                                                                                                                                                                                                                                                          
   Neither                                                                           1,015                                     44.9                                           0.8 (0.4, 1.9)[^*b*^](#t1n2){ref-type="table-fn"}                                          (Reference)
   WIC only                                                                          701                                       18.9                                           2.9 (1.5, 5.7)[^*b*^](#t1n2){ref-type="table-fn"}                                             0.02
   Medicaid only                                                                     366                                       10.8                                           3.7 (1.6, 8.2)[^*b*^](#t1n2){ref-type="table-fn"}                                           $< 0.001$
   Both WIC and Medicaid                                                             1,098                                     25.4                                           2.3 (1.6, 3.5)                                                                                0.01
  WIC eligibility[^*e*^](#t1n5){ref-type="table-fn"} among neither in WIC/Medicaid                                                                                                                                                                                             
   Not eligible or unknown                                                           725                                       34.7                                           0.4 (0.1, 1.8)                                                                             (Reference)
   Eligible                                                                          290                                       10.1                                           2.3 (1.0, 5.1)                                                                                0.04
  Urbanization                                                                                                                                                                                                                                                                 
   Large metro                                                                       1,798                                     49.0                                           1.5 (1.0, 2.2)                                                                             (Reference)
   Medium and small metro                                                            852                                       29.7                                           2.6 (1.2, 5.8)[^*b*^](#t1n2){ref-type="table-fn"}                                             0.21
   Non-metro                                                                         530                                       21.3                                           2.0 (0.9, 4.3)[^*b*^](#t1n2){ref-type="table-fn"}                                             0.50

Note: Large metro, MSAs with a population of 1 million or more; Medium and small metro, MSAs with a population of less than 1 million; MSA, metropolitan statistical areas; Non-metro, outside of MSAs; RSE, relative standard error.

*p*-Value for testing difference from reference category.

RSE $> 30\%$. NHANES-based estimates with RSE $> 30\%$ historically have been considered unreliable ([@c11]).

Estimates were not shown separately for children of other race/Hispanic origin groups because the design of NHANES does not allow reliable estimation for them due to small sample size.

Statistically significant difference from non-Hispanic black ($p = 0.002$).

WIC eligibility was determined by a family income-to-poverty ratio (based on family income reported by child participant's family member) $\leq 1.85$.

###### 

Unadjusted and adjusted prevalence ratios (95% CIs) for high BLLs $\geq 5\;\mu g/\text{dL}$ among children 1--5 y of age: United States, 2007--2014.

Table 2 lists W I C or Medicaid status in the first column; the corresponding unadjusted prevalence ratio (95 percent confidence intervals) and adjusted prevalence ratio (95 percent confidence intervals) are listed in the other columns.

  WIC/Medicaid status   Unadjusted prevalence ratio (95% CI)                   Adjusted prevalence ratio[^*a*^](#t2n1){ref-type="table-fn"} (95% CI)
  --------------------- ------------------------------------------------------ -----------------------------------------------------------------------
  Neither               1.00 (reference)                                       1.00 (reference)
  WIC only              3.49 (1.28, 9.57)[^*b*^](#t2n2){ref-type="table-fn"}   3.29 (1.19, 9.09)[^*c*^](#t2n3){ref-type="table-fn"}
  Medicaid only         4.35 (2.04, 9.28)[^*b*^](#t2n2){ref-type="table-fn"}   4.56 (2.18, 9.55)[^*c*^](#t2n3){ref-type="table-fn"}
  Both                  2.78 (1.24, 6.25)[^*b*^](#t2n2){ref-type="table-fn"}   2.58 (1.18, 5.63)[^*c*^](#t2n3){ref-type="table-fn"}

Adjusted for age (1--2 vs. 3--5 y of age).

No statistically significant difference across three unadjusted prevalence ratios ($p = 0.66$).

No statistically significant difference across three adjusted prevalence ratios ($p = 0.45$).

###### 

Age group-specific prevalence ratios (95% CIs) for high BLLs $\geq 5\;\mu g/\text{dL}$ among children 1--2 and 3--5 y of age: United States, 2007--2014.

Table 3 lists W I C or Medicaid status in the first column; the corresponding prevalence ratio for age 1 to 2 years (95 percent confidence intervals) and prevalence ratio for age 3 to 5 years (95 percent confidence intervals) are listed in the other columns.

  WIC/Medicaid status   Prevalence ratio for age 1--2 y (95% CI)               Prevalence ratio for age 3--5 y[^*a*^](#t3n1){ref-type="table-fn"} (95% CI)
  --------------------- ------------------------------------------------------ -----------------------------------------------------------------------------
  Neither               1.00 (reference)                                       1.00 (reference)
  WIC only              3.18 (0.88, 11.4)[^*b*^](#t3n2){ref-type="table-fn"}   3.53 (0.93, 13.4)[^*b*^](#t3n2){ref-type="table-fn"}
  Medicaid only         2.53 (0.49, 13.1)[^*c*^](#t3n3){ref-type="table-fn"}   5.31 (2.42, 11.6)[^*c*^](#t3n3){ref-type="table-fn"}
  Both                  3.51 (1.32, 9.33)[^*d*^](#t3n4){ref-type="table-fn"}   1.45 (0.37, 5.70)[^*d*^](#t3n4){ref-type="table-fn"}

No statistically significant interaction between age group and WIC/Medicaid status ($p = 0.24$).

No statistically significant difference between the two age groups ($p = 0.90$).

No statistically significant difference between the two age groups ($p = 0.42$).

No statistically significant difference between the two age groups ($p = 0.26$).

The characteristics of the study population are shown in [Table 1](#t1){ref-type="table"}. Less than half (44.3%) of all the children 1--5 y of age participated in WIC (including those who were also enrolled in Medicaid). About one quarter (25.4%) of all the children were part of both federal assistance programs. Although WIC participation and Medicaid enrollment overlapped, 18.9% of the children were "WIC only" and 10.8% were "Medicaid only." Approximately one-tenth (10.1%) of the children were not in WIC or Medicaid yet were determined to be eligible for WIC participation according to their FIPR. WIC participation and Medicaid enrollment by age are shown in Figure S1. The proportion of WIC participants (represented by "WIC only" and "WIC and Medicaid") tended to decrease with age, whereas the proportion of Medicaid enrollees did not show this pattern.

The prevalence of high BLL ($\geq 5\;\mu g/\text{dL}$) in different population groups is also shown in [Table 1](#t1){ref-type="table"}. Overall, the prevalence of high BLL was 1.9% (95% CI: 1.3, 2.9) for the combined 8-y period. The estimated prevalence of high BLL was highest for non-Hispanic black children and lowest for Mexican American children, although neither of these estimates was statistically different from the estimate for non-Hispanic white children. The prevalence of high BLL was greater in WIC-participating children \[2.6% (95% CI: 1.7, 3.8)\] than in nonparticipating children \[1.4% (95% CI: 0.7, 2.9)\], although not significantly so ($p = 0.11$). Medicaid-enrolled children had a greater prevalence of high BLL than non-Medicaid--enrolled children \[2.7% (95% CI: 1.9, 4.0) vs. 1.5% (95% CI: 0.9, 2.5)\]. Based on the four WIC/Medicaid categories, the prevalence of high BLL was greater for "WIC only" \[2.9% (95% CI: 1.5, 5.7)\], "Medicaid only" \[3.7% (95% CI: 1.6, 8.2)\], and "both WIC and Medicaid" \[2.3% (95% CI: 1.6, 3.5)\] compared with "neither" \[0.8% (95% CI: 0.4, 1.9)\]. Children who were income-eligible for WIC in the "neither" category had a prevalence of high BLL greater than the rest of "neither" children \[2.3% (95% CI: 1.0, 5.2) vs. 0.4% (95% CI: 0.1, 1.8), $p = 0.04$\].

Prevalence ratios unadjusted and adjusted for age for the mutually exclusive four-categorization of WIC/Medicaid status are shown in [Table 2](#t2){ref-type="table"}. "WIC only," "Medicaid only," and "Both WIC and Medicaid" children had greater prevalence of high BLL than children who did not participate in either program (reference) with adjusted prevalence ratios (aPRs) of 3.29 (95% CI: 1.19, 9.09), 4.56 (95% CI: 2.18, 9.55), and 2.58 (95% CI: 1.18, 5.63), respectively. The difference between these three aPRs was not statistically significant ($p = 0.45$, based on testing whether all of the three prevalence ratios are the same), possibly due to very wide confidence intervals.

There was little evidence that age was an effect modifier of the association between WIC/Medicaid status and high BLL (interaction $p = 0.24$) ([Table 3](#t3){ref-type="table"}). Comparisons of unadjusted versus adjusted prevalence ratios revealed a minor impact of the age adjustment, with relative changes expressed as ($\text{unadjusted}\, –\,\text{adjusted}$)/adjusted being within $\pm 10\%$ for the three unadjusted--adjusted pairs of prevalence ratios.

No statistically significant effect modification was observed in the association between WIC/Medicaid status and high BLL by race/Hispanic origin or urbanization (see Table S4). Adjustment for race/Hispanic origin, urbanization, or both resulted in relatively minor changes (within $\pm 13\%$) in prevalence ratio estimates, with relative changes expressed as ($\text{unadjusted}\, –\,\text{adjusted}$)/adjusted (see Table S4). These results did not materially change with reweighting (see Table S5).

Discussion {#s4}
==========

Our comparison of children by the four-category WIC/Medicaid status revealed that children in either or both federal assistance programs ("WIC only," "Medicaid only," and "WIC and Medicaid") had about three to four times greater high BLL prevalence than children who did not participate in either of the federal assistance programs, with or without adjustment for age. "WIC only" children, who accounted for about 20% of the children, were not targeted by the earlier strategy of universal blood lead screening of Medicaid-enrolled children required by CMS ([@c19]). We confirmed that the association does not vary by age group (1--2 vs. 3--5 y), and adjustment for age group did not result in a substantial change in the prevalence ratios for the association. Thus, the association between WIC/Medicaid status and high BLL observed for the entire 1- to 5-y age group would be applicable to the 1- to 2-y age group as well. As mentioned in the "Introduction," children in economically disadvantaged families receiving public assistance such as WIC and Medicaid are thought to be more likely to have higher lead exposure from lead sources present in their housing, which tends to be old and poorly maintained.

It is important to note that children participating in WIC or enrolled in Medicaid do not include all children in low-income families. According to the USDA Food and Nutrition Service, which administers WIC at the federal level, among the children 1 to 4 y of age who were eligible for WIC based on family income, about half (50.2%) were not taking part in WIC in a given month in 2013 ([@c24]). As such, screening WIC and/or Medicaid participants would still miss some children who are income-eligible for WIC but not enrolled in either WIC or Medicaid. We found this group of children had a greater prevalence of high BLL than the children who were not participating in WIC and were income-ineligible or had unknown WIC eligibility status.

The main results from the four-category WIC/Medicaid status variable are not directly comparable to previously reported two-category comparisons regarding Medicaid enrollment or WIC participation (to our knowledge, no previous study investigated association between four-category WIC/Medicaid status and high BLL), yet the two-category comparisons of prevalence of high BLL shown in [Table 1](#t1){ref-type="table"} may be compared with the previous results. We found Medicaid-enrolled children to be more likely to have higher BLLs than non-Medicaid--enrolled children, as seen in previous national-level research based on nationally representative NHANES data collected for 1988--1994 ([@c13]), 1991--1994 ([@c8]), and 1999--2010 ([@c27]). Higher BLLs among WIC-participating children (vs. non-WIC--participating children) were reported in Wisconsin between 1996 and 2000 ([@c28]).

At the national level, an existing mandate for WIC programs has been already playing an important role in the early detection of high BLL: Federal regulations require that the parent or caretaker of WIC-participating children be asked about blood lead screening tests and, in the absence of existing screening results, a referral to health care provider be made such that blood lead testing should occur (M. Kealey, written communication, January 2015) and ([@c23]). This policy may have contributed to the higher rate for lead screening among WIC-participating children than among non-WIC--participating children reported for Atlanta, Georgia ([@c25]).

This study has some limitations. A screening strategy involving WIC-participating children as a target, if implemented, would target WIC-participating children when they first take part in WIC. Yet, the children we identified as WIC participants had taken part in WIC for some length of time. This would have rendered our estimates of WIC versus non-WIC differences biased as differences relevant to targeting WIC participants at the time they start participation. Specifically, the relevant WIC versus non-WIC differences would have been underestimated in our prevalence ratios because children's BLLs may have been lowered as a result of continued WIC participation, for example, through consumption of food rich in iron and calcium provided by WIC ([@c22]). Sufficient intake of these metals may suppress lead absorption through the gastrointestinal tract and thereby reduce BLLs as indicated by animal ([@c10]) and human ([@c16]) studies. Other components of WIC, for example, education and health referrals ([@c23]), may also have resulted in reductions in exposure to lead over time.

A misclassification issue arises from our definitions of WIC participation and Medicaid enrollment. Conceptually, the children who have never been in WIC or Medicaid would have been an ideal reference group. Yet our actual reference group of "neither in WIC/Medicaid" included some past WIC participants and Medicaid enrollees because the WIC/Medicaid status was determined only by the questions about WIC participation in the past 12 months and Medicaid enrollment status at the time of home interview. This misclassification may have introduced bias toward the null in our estimates of differences between referent and nonreferent WIC/Medicaid groups. Even with such a bias, though, our WIC/Medicaid prevalence ratios showed statistically significant elevations of a nontrivial size from the null value, implying that the misclassification had a relatively minor impact.

Another potential source of bias is the phlebotomy response rates for the children 1--5 y of age, which may have compromised the degree to which the analytic sample was representative of the underlying population. However, reweighting based on response rates by domains defined by race/Hispanic origin, sex, and age did not materially change the estimates, indicating nonresponse bias due to differential phlebotomy response across such domains would have been relatively small.

Finally, another limitation of the study is the relatively small sample sizes for some subgroups, resulting in wide confidence intervals for the estimated prevalence of high BLL. For instance, children who were enrolled only in Medicaid accounted for $< 10\%$ of the NHANES population studied, and prevalence estimates for this and other groups of relatively small sample size potentially are subject to more random error than prevalence estimates for other groups.

A strength of the present study is the use of a nationally representative sample to determine whether young children (1--2 y of age) who are enrolled in WIC but are not targeted for screening via Medicaid would benefit from an expanded screening program. We estimated age-adjusted prevalences of high BLL relevant to actual population, rather than statistically adjusting for additional covariates to estimate what the association between WIC/Medicaid status and high BLL would be if all other factors were held constant.

Conclusions {#s5}
===========

Our estimates suggest that children participating in WIC, Medicaid, or both federal assistance programs were all more likely to have high BLLs than children who were not participating in WIC nor enrolled in Medicaid. We confirmed that this finding would be applicable to children 1--2 y of age, the age range targeted by the current childhood blood lead screening required by CMS. Our results indicate that the CDC's 2012 recommendation of targeting WIC participants for screening would identify additional children with high BLL.

Supplemental Material
=====================
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Click here for additional data file.
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